Ascendis Pharma to Host Oncology Program Update on May 31
25 Maio 2023 - 9:30AM
Ascendis Pharma A/S (Nasdaq: ASND) today announced the company will
host an Oncology program update for the investment community on
Wednesday, May 31, 2023 in New York from 10:00 a.m. to 12:00 p.m.
Eastern Time.
The event will feature presentations by an outside oncology
expert and Ascendis senior management on the company’s two
immuno-oncology product candidates, TransCon IL-2 β/γ and TransCon
TLR7/8 Agonist, being investigated as both mono- and combination
therapies. Topics will include clinical development strategy and
clinical development program updates, including monotherapy
clinical data on TransCon IL-2 β/γ used to define the
recommended Phase 2 dose.
Those who would like to participate may access the live webcast
here. The link to the live webcast will also be available on the
Investors & News section of the Ascendis Pharma website at
https://investors.ascendispharma.com. A replay of the webcast will
be available on this section of our website shortly after
conclusion of the event for 30 days.
About Ascendis Pharma A/SAscendis Pharma is
applying its innovative TransCon technology platform to build a
leading, fully integrated, global biopharma company focused on
making a meaningful difference in patients’ lives. Guided by its
core values of patients, science and passion, the company uses its
TransCon technologies to create new and potentially best-in-class
therapies. Ascendis is headquartered in Copenhagen, Denmark, and
has additional facilities in Germany (Heidelberg, Berlin and
Munich) and the United States (Palo Alto and Redwood City,
California, and Princeton, New Jersey). Visit ascendispharma.com to
learn more.
Forward-Looking Statements This press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of
historical facts, included in this press release regarding
Ascendis’ future operations, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to (i) Ascendis’
ability to apply its TransCon technology platform to build a
leading, fully integrated, global biopharma company, and (ii)
Ascendis’ use of its TransCon technologies to create new and
potentially best-in-class therapies. Ascendis may not actually
achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that Ascendis makes, including
the following: dependence on third party manufacturers,
distributors and service providers for Ascendis’ products and
product candidates; unforeseen safety or efficacy results in its
development programs or on-market products; unforeseen expenses
related to commercialization of any approved Ascendis products;
unforeseen expenses related to Ascendis’ development programs;
unforeseen selling, general and administrative expenses, other
research and development expenses and Ascendis’ business generally;
delays in the development of its programs related to manufacturing,
regulatory requirements, speed of patient recruitment or other
unforeseen delays; Ascendis’ ability to obtain additional funding,
if needed, to support its business activities; the impact of
international economic, political, legal, compliance, social and
business factors, including inflation, and the effects on its
business from the worldwide COVID-19 pandemic and ongoing conflicts
such as that in the region surrounding Ukraine and Russia. For a
further description of the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Ascendis’
business in general, see Ascendis’ Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission (SEC) on February
16, 2023 and Ascendis’ other future reports filed with, or
submitted to, the SEC. Forward-looking statements do not reflect
the potential impact of any future licensing, collaborations,
acquisitions, mergers, dispositions, joint ventures, or investments
that Ascendis may enter into or make. Ascendis does not assume any
obligation to update any forward-looking statements, except as
required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company
logo, and TransCon are trademarks owned by the Ascendis Pharma
group. © May 2023 Ascendis Pharma A/S.
Investor Contacts: |
|
Media
Contact: |
Tim Lee |
|
Melinda Baker |
Ascendis Pharma |
|
Ascendis Pharma |
+1 (650) 374-6343 |
|
+1 (650) 709-8875 |
tle@ascendispharma.com |
|
media@ascendispharma.com |
ir@ascendispharma.com |
|
|
|
|
|
Patti Bank |
|
|
ICR Westwicke |
|
|
+1 (415) 513-1284 |
|
|
patti.bank@westwicke.com |
|
|
Ascendis Pharma AS (NASDAQ:ASND)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Ascendis Pharma AS (NASDAQ:ASND)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024